Dr. Katz on Preoperative Chemotherapy in Resectable Pancreatic Cancer

Video

In Partnership With:

Matthew H.G. Katz, MD, FACS, discusses the utility of preoperative chemotherapy for patients with resectable pancreatic cancer.

Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the utility of preoperative chemotherapy for patients with resectable pancreatic cancer.

Surgical resection followed by 6 months of systemic chemotherapy has been the mainstay of treatment for patients with resectable pancreatic cancer for many years, says Katz. Currently, the standard of care for these patients is pancreaticoduodenectomy or distal pancreatectomy followed by FOLFIRNOX.

However, current ASCO guidelines recommend the administration of preoperative systemic chemotherapy for patients who have large or anatomically advanced tumors, patients with poor performance status that renders them ineligible for upfront surgery, and patients with occult metastatic disease detected with imaging or elevated CA 19-9 levels, concludes Katz.

While preoperative chemotherapy has not been adopted as the standard of care in this patient population, it can be considered in the right patient, explains Katz. Preoperative radiation therapy may provide additional benefit for these patients, concludes Katz.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,